Table 1 Characteristics of study population
Total Post-COVID-19 syndrome Non-post-COVID-19 syndrome
Patients (%) n = 123 n = 33 n = 90
Gender (female) (%) 47 (38.2%) 17 (51.5%) 30 (33.3%)
Gender (male) (%) 76 (61.8%) 16 (48.5%) 60 (66.7%)
Age (years), mean ± SD 62.1 ± 9.5 58.5 ± 10.6 63.4 ± 8.8
Comorbidity (%)
Direct influence on COVID-19a
85 (69.1%)
20 (60.6%)
65 (72.2%)
Indirect influence on COVID-19b
38 (30.9%)
13 (39.4%)
25 (27.8%)
COVID severityc (%)
Low
53 (43.1%)
14 (42.4%)
39 (43.3%)
Low-medium
8 (6.5%)
0 (0.0%)
8 (8.9%)
Medium
24 (19.5%)
6 (18.2%)
18 (20.0%)
High
38 (30.9%)
13 (39.4%)
25 (27.8%)
Drug treatment
Antibiotics
89 (72.4%)
24 (72.7%)
65 (72.2%)
Anticoagulants
100 (81.3%)
25 (75.8%)
75 (83.3%)
Corticosteroids
73 (59.3%)
16 (48.5%)
57 (63.3%)
Antibiotic + Anticoagulant
71 (57.7%)
18 (54.5%)
53 (58.9%)
Antibiotic + Corticosteroids
53 (43.1%)
13 (39.4%)
40 (44.4%)
Anticoagulant + Corticosteroid
64 (52.0%)
13 (39.4%)
51 (56.7%)
Antibiotic + Anticoagulant + corticosteroid
46 (37.4%)
11 (33.3%)
35 (38.9%)
Hospital stay duration (days), mean ± SD 12.5 ± 11.3 10.2 ± 8.6 13.3 ± 12.1